Imunon (IMNN) Stock Overview
A clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
IMNN Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Imunon, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.55 |
| 52 Week High | US$41.22 |
| 52 Week Low | US$2.50 |
| Beta | 2.03 |
| 1 Month Change | -17.74% |
| 3 Month Change | -21.54% |
| 1 Year Change | -65.19% |
| 3 Year Change | -85.73% |
| 5 Year Change | -98.89% |
| Change since IPO | -99.90% |
Recent News & Updates
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
Catalysts About Imunon Imunon is a clinical stage biotechnology company focused on developing IMNN-001, an IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?
Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
Catalysts About Imunon Imunon is a clinical stage biotechnology company developing IMNN-001, an intraperitoneal IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?Recent updates
Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy
Catalysts About Imunon Imunon is a clinical stage biotechnology company focused on developing IMNN-001, an IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis
Catalysts About Imunon Imunon is a clinical stage biotechnology company developing IMNN-001, an intraperitoneal IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?Shareholder Returns
| IMNN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 1.0% | 1.1% |
| 1Y | -65.2% | 40.3% | 26.7% |
Return vs Industry: IMNN underperformed the US Biotechs industry which returned 44.4% over the past year.
Return vs Market: IMNN underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| IMNN volatility | |
|---|---|
| IMNN Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMNN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMNN's weekly volatility has decreased from 32% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 25 | Stacy Lindborg | imunon.com |
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
Imunon, Inc. Fundamentals Summary
| IMNN fundamental statistics | |
|---|---|
| Market cap | US$10.20m |
| Earnings (TTM) | -US$14.64m |
| Revenue (TTM) | n/a |
Is IMNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.64m |
| Earnings | -US$14.64m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 04:59 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imunon, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |